Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2015-01-09)Premium Content

Sanofi (SNY)

2015-03-27@08:32:27 ET
Bottom 5 Companies in the Pharmaceuticals Industry with the Lowest Relative Performance (SCMP, XNPT, SNY, RDY, DEPO) (F70)

2015-03-26@17:18:31 ET
Look for Shares of Sanofi-Aventis to Potentially Rebound after Yesterday's 2.98% Sell Off (PSM)

2015-03-26@17:18:01 ET
After Yesterday's Decline of 2.98%, Sanofi-Aventis Offers Investors Better Value (PSM)

2015-03-26@14:20:33 ET
Volume Spike Detected in Shares of Sanofi-Aventis as They Move Lower on 1.3x Above-Average Volume (SNY) (F82)

2015-03-26@13:30:00 ET
Genzyme Convenes Sixth Annual Gaucher Leadership Forum (BIZ)

2015-03-26@11:50:33 ET
Sanofi-Aventis Shares Sinking Lower, Down 1.6% (F77)

2015-03-25@21:12:00 ET
ENCORE Clinical Data Published in The Lancet Suggest Treatment with Oral Maintenance Therapy Effective in Previously Treated Gaucher Disease Patients (BIZ)

2015-03-25@12:15:00 ET
Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years of Age (PRN)

2015-03-24@10:10:07 ET
Sanofi-Aventis Fulfills the Promise: Up 4.9% Since Last Week's Upgrade (F70)

2015-03-20@08:28:55 ET
Short-term Underperformance Detected in Shares of Nektar Therapeutics in the Pharmaceuticals Industry (NKTR, NVO, PRGO, MYL, SNY) (F70)

2015-03-19@13:13:56 ET
Shares of Sanofi-Aventis Under Pressure, Down 1.5% (F77)

2015-03-19@07:00:00 ET
(PRN)

2015-03-18@08:45:00 ET
(PRN)

2015-03-17@08:28:23 ET
Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of XenoPort (XNPT, AKRX, SNY, PRGO, MDCO) (F70)

2015-03-17@08:07:40 ET
Upgrade Alert for Sanofi-Aventis (SNY) (PSM)

2015-03-16@12:57:28 ET
Bullish Moving Average Cross by Sanofi-Aventis (SNY) (F78)

2015-03-16@11:28:11 ET
Shares of Sanofi-Aventis Receive a Boost, Up 3.5% (F77)

2015-03-15@11:00:00 ET
Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine (PRN)

2015-03-15@11:00:00 ET
Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine (PRN)

2015-03-13@10:16:41 ET
Patients With Advanced Prostate or Colorectal Cancer Face an Uncertainty in Their Future Treatment After NHS England Decision (EUR)